Annual report pursuant to Section 13 and 15(d)

Note 4 - Fair Value Measurements (Details Textual)

v3.7.0.1
Note 4 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2017
Jun. 30, 2017
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Aug. 01, 2016
Mar. 14, 2016
Nov. 03, 2014
Payment for Contingent Consideration Liability   $ 28,500            
Payment for Contingent Consideration Liability, Financing Activities   16,700 $ 21,060      
Payment for Contingent Consideration Liability, Operating Activities   11,800            
CyVek, Inc. [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   35,000 35,000          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized   35,000 35,000 $ 35,000       $ 35,000
Zephyrus [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   7,000 7,000       $ 7,000  
Business Combination, Liabilities Arising from Contingencies, Amount Recognized             $ 6,500  
Payment for Contingent Consideration Liability   3,500            
Payment for Contingent Consideration Liability, Financing Activities $ 3,500              
Advanced Cell Diagnostics (ACD) [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   75,000 75,000     $ 75,000    
Business Combination, Liabilities Arising from Contingencies, Amount Recognized           $ 37,000    
Payment for Contingent Consideration Liability   25,000            
Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member]                
Business Combination, Liabilities Arising from Contingencies, Amount Recognized   $ 78,500 $ 78,500